Nevirapine Viatris

Nevirapine, the active ingredient in Nevirapine Viatris, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is indicated for the treatment of HIV‑1 infection in adults, adolescents and children as part of combination antiretroviral therapy.

GNH USA supplies Nevirapine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is a non‑nucleoside reverse transcriptase inhibitor used in the management of HIV‑1 infection.

- HIV‑1 infection (adults and adolescents): suppresses viral replication when combined with other antiretrovirals. - Pediatric HIV‑1 infection (≥2 years): contributes to viral load reduction as part of a pediatric regimen. - Treatment‑experienced HIV‑1 infection: provides an option for patients with resistance to other NNRTIs.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal upset. - Fatigue: feeling of tiredness. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness. - Abdominal pain: mild discomfort.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic failure: signs of liver toxicity such as jaundice. - Severe hypersensitivity: systemic allergic response. - Neutropenia: marked reduction in white blood cells. - Anemia: significant drop in red blood cell count. - Life‑threatening skin reactions: toxic epidermal necrolysis.

Before initiating therapy, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline enzymes and repeat periodically. - Rash assessment: discontinue promptly if severe or progressing. - Hepatic impairment: avoid or adjust dose in patients with severe liver disease. - Pregnancy considerations: evaluate risk‑benefit ratio before use. - Drug interaction review: check concomitant medications for potential interactions. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Nevirapine interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Rifampin: reduces nevirapine plasma concentrations. - St. John’s wort: induces metabolism, lowering drug levels. - Protease inhibitors (e.g., ritonavir): may increase toxicity.

Moderate Interactions (Monitor Closely): - Efavirenz: may increase risk of hepatotoxicity. - Fluconazole: can raise nevirapine concentrations, requiring monitoring.